AstraZeneca and Daiichi Sankyo's Enhertu recommended for approval
15th Sep 2023 15:27
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd's Enhertu has been recommended for approval in the EU on Friday. Read More
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd's Enhertu has been recommended for approval in the EU on Friday. Read More
(Alliance News) - Smith & Nephew PLC on Thursday announced that BT Group PLC's chief financial officer, Simon Lowth, will join the board as independent non-executive director on January 1. Read More
(Alliance News) - AstraZeneca PLC on Monday said that its therapy, Fasenra, met the primary endpoint in the Mandara phase three trial in eosinophilic granulomatosis with polyangiitis. Read More
(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for lung cancer, while also seeing "strong and durable" tumour responses from its Enhertu antibody drug conjugate. Read More
(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data. Read More
(Alliance News) - AstraZeneca PLC reported positive clinical results of combinations of its Imfinzi and Tagrisso drugs with other treatments for cancer. Read More
(Alliance News) - AstraZeneca PLC on Wednesday said it is working closely with the US Food & Drug Administration regarding a request to changes to improve risk evaluation for Ultomiris. Read More
(Alliance News) - Stock prices in London were higher at midday on Monday, with market mood buoyed by news of stimulus measures in China and increasing optimism for the future of interest rates across the Atlantic. Read More
AstraZeneca PLC - Cambridge-based pharmaceutical maker - Astra's Calquence is approved in China for treatment of chronic lymphocytic leukaemia or small lymphocytic lymphoma in adult patients who have received at least one prior therapy. The National Medical Products Administration approves Calquence, whose generic name is acalabrutinib, based on two different trials, including one in China. Astra notes that CLL is the most prevalent type of adult leukaemia around the world and represents about 6.4% of B-cell non-Hodgkin lymphoma patients in China. Calquence already is approved for treatment of CLL and SLL in the US and Japan and is approved for CLL in the EU. Read More
(Alliance News) - Stocks in London are expected to open on a positive note on Monday, amid an improvement in global risk sentiment. Read More
(Alliance News) - AstraZeneca PLC and Merck & Co Inc on Thursday jointly said its Lynparza treatments have been approved in Japan. Read More
(Alliance News) - AstraZeneca PLC on Thursday said both its Soliris and Lynparza treatments have been approved in Japan. Read More
(Alliance News) - Stocks in Europe were on the up heading into Wednesday afternoon, with equity markets in a confident mood on the eve of the Jackson Hole central banking event, shaking off tepid economic data which hurt the pound and euro. Read More
(Alliance News) - AstraZeneca PLC's partner Daiichi Sankyo Co Ltd on Wednesday announced that their cancer drug Enhertu has received another approval in Japan. Read More
(Alliance News) - The bosses of Britain's biggest companies saw their pay surge by 16% last year as most workers saw their pay packets outstripped by inflation, according to new research. Read More
(Alliance News) - AstraZeneca PLC on Monday announced that new data from its studies show positive effects of Forxiga on people with heart failure. Read More
(Alliance News) - AstraZeneca PLC on Friday said its drug Forxiga has been approved in China for some adults to reduce the risk of cardiovascular death and hospitalisation. Read More
(Alliance News) - Cizzle Biotechnology PLC and Vela Technologies PLC on Tuesday noted that blank-check special purpose acquisition company Murphy Canyon Acquisition Corp will hold a special meeting on September 7. Read More
(Alliance News) - London's FTSE 100 underwhelmed on Thursday, as a slew of its heavyweights went ex-dividend, though blue-chip equities in mainland Europe were higher, showing no signs of pre-US inflation data angst and overlooking an acceleration in tensions between the world's two largest economies. Read More